

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier's details

Company name of supplier : MSD
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 4
Acute toxicity (Inhalation) : Category 4
Skin corrosion/irritation : Category 2
Serious eye damage/eye irritation : Category 2A
Reproductive toxicity : Category 1B
Specific target organ toxicity - single exposure (Oral) : Category 1 (Central nervous system)
Specific target organ toxicity - single exposure : Category 3
Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H302 + H332 Harmful if swallowed or if inhaled.
H315 Causes skin irritation.

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360Df May damage the unborn child. Suspected of damaging fertility.
H370 Causes damage to organs (Central nervous system) if swallowed.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Precautionary Statements

: **Prevention:**

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/ physician if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Components

Chemical name	CAS-No.	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	>= 20 -< 30
Ivermectin	70288-86-7	>= 1 -< 5
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 5
(dl)-a-Tocopheryl acetate	7695-91-2	< 0.1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Harmful if swallowed or if inhaled.
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
May damage the unborn child. Suspected of damaging fertility.
Causes damage to organs if swallowed.
Causes damage to organs through prolonged or repeated exposure if swallowed.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NOx)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
	Further information: Skin			
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	Wipe limit	300 µg/100 cm ²	Internal
		TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 ug/m3 (OEB 1)	Internal
---------------------------	-----------	-----	--------------------	----------

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift	100 mg/l	MX BEI
		5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

Engineering measures

- Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection	<ul style="list-style-type: none">If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	<ul style="list-style-type: none">Combined particulates and organic vapor type
Hand protection	
Material	<ul style="list-style-type: none">Chemical-resistant gloves
Remarks	<ul style="list-style-type: none">Consider double gloving.
Eye protection	<ul style="list-style-type: none">Wear safety glasses with side shields or goggles.If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	<ul style="list-style-type: none">Work uniform or laboratory coat.Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Appearance	:	liquid
Color	:	light yellow
Odor	:	characteristic
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 100 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	0.91 - 1.00 mg/l
Solubility(ies)		
Water solubility	:	insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023 Date of first issue: 10.01.2017

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation

Skin contact

Ingestion

Eye contact

Acute toxicity

Harmful if swallowed or if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 981.33 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg
Method: OECD Test Guideline 401
Remarks: The test was conducted equivalent or similar to guideline

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: The test was conducted according to guideline

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2	Revision Date: 03.02.2025	SDS Number: 1210013-00024	Date of last issue: 30.09.2023 Date of first issue: 10.01.2017
----------------	------------------------------	------------------------------	---

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 402
Remarks: The test was conducted equivalent or similar to guideline

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

(dl)-a-Tocopheryl acetate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:

N-Methyl-2-pyrrolidone:

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2	Revision Date: 03.02.2025	SDS Number: 1210013-00024	Date of last issue: 30.09.2023 Date of first issue: 10.01.2017
----------------	------------------------------	------------------------------	---

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Rabbit
Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : No skin irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

N-Methyl-2-pyrrolidone:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Rabbit
Result : Mild eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : Mild eye irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ivermectin / Abamectin Liquid FormulationVersion
7.2Revision Date:
03.02.2025SDS Number:
1210013-00024Date of last issue: 30.09.2023
Date of first issue: 10.01.2017**Components:****N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative
Remarks : Based on data from similar materials

Ivermectin:

Routes of exposure : Dermal
Species : Humans
Result : Does not cause skin sensitization.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximization Test
Routes of exposure : Skin contact
Result : Not a skin sensitizer.

(dl)-a-Tocopheryl acetate:

Test Type : Draize Test
Routes of exposure : Skin contact
Species : Humans
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: The test was conducted according to guideline

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: The test was conducted according to guideline

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Method: OECD Test Guideline 482
Result: negative
Remarks: The test was conducted equivalent or similar to guideline

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative
Remarks: The test was conducted according to guideline

Ivermectin:

Genotoxicity in vitro

- : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative
- Test Type: Mouse Lymphoma
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro

- : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
- Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
- Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo

- : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

(dl)-a-Tocopheryl acetate:

Genotoxicity in vitro

- : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
- Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo

- : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Components:

N-Methyl-2-pyrrolidone:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Method	:	OECD Test Guideline 451
Result	:	negative
Remarks	:	The test was conducted according to guideline
Species	:	Rat
Application Route	:	Inhalation
Exposure time	:	2 Years
Method	:	OECD Test Guideline 453
Result	:	negative
Remarks	:	The test was conducted equivalent or similar to guideline

Ivermectin:

Species	:	Rat
Application Route	:	Oral
NOAEL	:	1.5 mg/kg body weight
Result	:	negative
Remarks	:	Based on data from similar materials
Species	:	Mouse
Application Route	:	Oral
NOAEL	:	2.0 mg/kg body weight
Result	:	negative
Remarks	:	Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	:	Rat
Application Route	:	Oral
Exposure time	:	105 weeks
Result	:	negative
Species	:	Mouse
Application Route	:	Oral
Exposure time	:	93 weeks
Result	:	negative

(dl)-a-Tocopheryl acetate:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	104 weeks
Result	:	negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

N-Methyl-2-pyrrolidone:

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2	Revision Date: 03.02.2025	SDS Number: 1210013-00024	Date of last issue: 30.09.2023 Date of first issue: 10.01.2017
----------------	------------------------------	------------------------------	---

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: The test was conducted according to guideline

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted according to guideline

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapor)
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Ivermectin / Abamectin Liquid Formulation

Version 7.2	Revision Date: 03.02.2025	SDS Number: 1210013-00024	Date of last issue: 30.09.2023 Date of first issue: 10.01.2017
----------------	------------------------------	------------------------------	---

Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects., Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023 Date of first issue: 10.01.2017

Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

STOT-single exposure

May cause respiratory irritation.
Causes damage to organs (Central nervous system) if swallowed.

Components:

N-Methyl-2-pyrrolidone:

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Routes of exposure : Ingestion
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

N-Methyl-2-pyrrolidone:

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408
Remarks : The test was conducted according to guideline

Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Species : Rat
NOAEL : 0.5 mg/l
LOAEL : 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 96 Days
Method : OECD Test Guideline 413
Remarks : The test was conducted according to guideline

Species : Rabbit, male
NOAEL : 826 mg/kg
LOAEL : 1,653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days
Method : OECD Test Guideline 410
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : spleen, Bone marrow, Kidney

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023 Date of first issue: 10.01.2017

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system

(dl)-a-Tocopheryl acetate:

Species : Rat
NOAEL : 500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.
Eye contact : Remarks: May irritate eyes.
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023 Date of first issue: 10.01.2017

Method: DIN 38412

Remarks: The test was conducted according to guideline

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: The test was conducted according to guideline

Toxicity to microorganisms : EC50 (activated sludge): > 600 mg/l
Exposure time: 30 min
Method: ISO 8192
Remarks: The test was conducted according to guideline

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.03 µg/l
Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
Exposure time: 28 d

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

(dl)-a-Tocopheryl acetate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
Exposure time: 28 d

Toxicity to microorganisms : EC50: > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Persistence and degradability**Components:****N-Methyl-2-pyrrolidone:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C
Remarks: The test was conducted according to guideline

Ivermectin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 21.7 - 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46
Method: OECD Test Guideline 107
Remarks: The test was conducted according to guideline

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

Mobility in soil**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3.6

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version 7.2 Revision Date: 03.02.2025 SDS Number: 1210013-00024 Date of last issue: 30.09.2023 Date of first issue: 10.01.2017

Domestic regulation

NOM-002-SCT

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)
Class : 9
Packing group : III
Labels : 9

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 03.02.2025
Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
MX BEI : Official Mexican Norm NOM-047-SSA1-2011, Environmental Health - Biological exposure indices for workers occupationally exposed to chemical agents

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

SAFETY DATA SHEET



Ivermectin / Abamectin Liquid Formulation

Version
7.2

Revision Date:
03.02.2025

SDS Number:
1210013-00024

Date of last issue: 30.09.2023
Date of first issue: 10.01.2017

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8